Protection cardiorénale avec les inhibiteurs des SGLT2 : d’EMPA-REG OUTCOME à VERTIS CV.

[en] The landmark study EMPA-REG OUTCOME firstly demonstrated both a cardiovascular and renal protection with empagliflozin in patients with type 2 diabetes (T2DM) and established cardiovascular disease. Since 2015, two other trials showed a reduction in the hospitalisations for heart failure and the progression of the renal disease, also in patients with multiple risk factors, CANVAS with canagliflozin and DECLARE-TIMI 58 with dapagliflozin. CREDENCE (canagliflozin in T2DM patients with kidney disease) confirmed a renal protection and DAPA-HF (dapagliflozin in patients, with or without T2DM, but reduced ejection fraction) showed a less acute deterioration of heart failure. The positive effect of SGLT2 inhibitors on heart failure predominates, an effect recently confirmed in VERTIS CV with ertugliflozin.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

French

Title :

Protection cardiorénale avec les inhibiteurs des SGLT2 : d’EMPA-REG OUTCOME à VERTIS CV.

Alternative titles :

[en] Cardiovascular and renal protection with SGLT2 inhibitors: from EMPA-REG OUTCOME to VERTIS CV

Publication date :

2020

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

Issue :

703

Pages :

1483-1488

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 31 August 2020

Statistics

Number of views

127 (4 by ULiège)

Number of downloads

4 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

See more details

Bibliography

Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020;63:221-8.
**Scheen AJ, Paquot N. Traitement des patients diabétiques de type 2 à risque cardiorénal: ESC versus ADA-EASD. Rev Med Suisse 2020;16:1478-82.
Scheen AJ. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res 2018;122:1439-59.
Scheen AJ. Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Rev Endocrinol 2020;epub ahead of print.
*Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34.
Scheen AJ, Wallemacq C, Jandrain B, et al. Protection cardiovasculaire du patient diabétique de type 2: d’EMPAREG OUTCOME à LEADER. Rev Med Suisse 2016;12:1370-5.
Scheen AJ. Focus sur l’empagliflozine: synthèse des analyses post-hoc de l’étude cardiovasculaire EMPA-REG OUTCOME. Rev Med Liege 2019;74:185-91.
*Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-57.
*Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-57.
Scheen AJ, Ernest P, Jandrain B. Protection cardio-rénale par les inhibiteurs des SGLT2 (gliflozines): d’EM-PA-REG OUTCOME à CANVAS. Rev Med Suisse 2017;13:1421-6.
*Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-306.
*McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008.
Scheen AJ. Canagliflozine et protection cardio-rénale chez le patient diabétique de type 2: de CANVAS à CREDENCE. Rev Med Liege 2019;74:508-13.
Cannon C. VERTIS CV: cardiovascular and renal outcomes. Présentation au congrès de l’American Diabetes Association, Chicago,16 juin 2020. Disponible sur: www.acc.org/education-and-meetings/image-and-slide-gallery/media-detai l?id=307A7E103BC04A588A3370709253 FC35 (dernier accès 20 juin 2020).
Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J 2018;206:11-23.
*Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31-9.
Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 2019;139:2022-31.
Scheen AJ, Paquot N. Inhibiteur des SGLT2 ou analogue du GLP-1 chez un patient diabétique avec maladie cardiovasculaire ? Rev Med Suisse 2018;14:1460-5.
Heerspink HJL, Stefansson BV, Chertow GM, et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant 2020;35:274-82.
Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776-85.
Scheen AJ. Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract 2018;143:88-100.
Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects. Potential mechanisms and clinical applications. Circulation 2016;134:752-72.
Anker SD, Butler J, Filippatos GS, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail 2019;21:1279-87.
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41:255-323.
Scheen AJ, Paquot N. Extension des indications pour les antidiabétiques avec protection cardio-rénale dans les dernières recommandations internationales pour la prise en charge du patient diabétique de type 2. Rev Med Liege 2020;75:233-9.
Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Safety 2019;18:295-311.
Bauduceau B, Bordier L, Bordier L, et al. Prise de position de la SFD: évaluation du rapport bénéfices-risques des inhibiteurs de SGLT2. Med Mal Metab 2019;13:195-209.
Scheen AJ. À propos de l’expérience belge avec les inhibiteurs des SGLT2. Med Mal Metab 2020;14:320-30.